Sebastian Voicu
Paris, 75010, France
Location status: Recruiting
NCT Number: NCT07201311
Gastrointestinal absorption of high dose medication (toxicant) ingested under solid form for suicidal purposes, is prolonged in patients who need intensive care admission and mechanical ventilation. This is due to the large ingested amounts, slowed blood circulation in the digestive system due to low blood pressure, and the formation of conglomerates of pills (pharmacobezoars).
We make the hypothesis that combined decontamination of the digestive system with activated charcoal plus polyethylene glycol may reduce absorption of the ingested toxicant compared with standard care.
Two hundred patients requiring admission to intensive care and mechanical ventilation due to the effect of the ingested toxicant, will be included in a 1:1 randomized fashion over 24 months in the intervention group receiving combined decontamination and standard care group receiving activated charcoal according to guidelines.
The main objective is to show a decrease in the concentration of the toxicant after 24h of randomization.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 2
Paris, 75010, France
Location status: Recruiting
Rationale - digestive absorption of toxic substances ingested in solid form is prolonged in severely intoxicated patients admitted to intensive care and requiring intubation and mechanical ventilation. This prolonged absorption is favoured by the large quantity of tablets/pills ingested, the formation of pharmacobezoars, delayed formulations, co-ingestion of transit slowing agents (such as substances with an anticholinergic effect) and mesenteric hypoperfusion in the event of hypotension slowing absorption.
Digestive decontamination with activated charcoal combined with intestinal purging with polyethylene glycol (PEG) appears to be effective in pharmacokinetic studies, but its benefits have never been studied in intoxicated patients, particularly after admission to intensive care. Digestive decontamination using activated charcoal and polyethylene glycol could reduce toxic concentrations at 24 hours compared with the standard treatment group.
Main objective: To show the greatest reduction in the plasma concentration of the toxicant(s) (ingested parent molecules) at H24 of randomisation in the intervention group receiving activated charcoal + intestinal purge compared with the control group.
primary endpoint: Percentage change in the plasma concentration of the toxic substance(s) (ingested parent molecules) at 24 hours compared with its/their value(s) at randomisation.
Secondary objectives:
Secondary endpoints:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patient aged ≥18, intoxicated and hospitalised in intensive care AND
Exclusion criteria
A dose of 25-100g of activated charcoal via the nasogastric tube will be administered, followed by polyethylene glycol1L/15-20 kg ideal body weight at a flow rate of 1L/hour.
polyethylene glycol will be continued until clear stools are obtained, a maximum of 24h of treatment of until the maximum dose of 1L per 15 kg of ideal body weight are administered.
Serial activated charcoal 50g 6 times/day will be administered if prolonged-release forms or drugs with enterohepatic circulation were ingested.
Patients receive activated charcoal according to French guidelines - activated charcoal 25-100g and serial activated charcoal 50g 6 times/day if sustained-release forms or drugs with enterohepatic circulation as routine treatment.
Time frame: 24 hours post-randomization
The primary endpoint is the percentage change in the plasma concentration of the toxic substance at 24 hours compared with the value at randomization.
The percentage variation is calculated as 100 x (Concentration at 24 hours post-randomization-Concentration at randomization)/ Concentration at randomization
Time frame: 48, 72 and 96 hours post-randomization
The percentage variation is calculated as:
At 48 hours : 100 x (Concentration at 48 hours post-randomization-Concentration at randomization)/ Concentration at randomization At 72 hours : 100 x (Concentration at 48 hours post-randomization-Concentration at randomization)/ Concentration at randomization At 96 hours : 100 x (Concentration at 48 hours post-randomization-Concentration at randomization)/ Concentration at randomization
Time frame: 96 hours post-randomization
All concentrations up to the 96th hour post-randomization will be used to generate the area under the curve, and this will be reported as percentage of the concentration at randomization
Time frame: 28 days post randomization
Patients who leave the hospital after extubation and before the 28th day of randomization will be considered as being free of mechanical ventilation from extubation to the 28th day post randomization
Time frame: 28 days post randomization
This will be defined as the interval from the moment the patient is ready to leave the intensive care until the 28th day of randomization. This will avoid lengthening the theoretical duration of ICU stay due to lack of ward beds
Time frame: through the study complétion, an average of 7 days
The polyethylene glycol and activated charcoal may induce vomiting, therefore the number of vomiting episodes will be recorded and compared between groups
Time frame: through the study complétion, an average of 7 days
Number of pneumonias occurring through the study completion, an average of 7 days
Time frame: through the study complétion, an average of 7 days
Polyethyleneglycol may cause upper abdominal pain, therefore the number of upper abdominal pain episodes will be recorded and compared between groups
Time frame: through the study complétion, an average of 7 days
Diarrhea is a therapeutic effect of the polyethylene glycol, therefore the number of diarrhea episodes will be recorded and compared between groups
Time frame: through the study complétion, an average of 7 days
Polyethylene glycol may cause allergic reactions such as anaphylactic shock, angioedema, urticaria, rash and pruritus, therefore the presence of allergic reactions will be recorded and compared between groups
Contact information is provided by the study sponsor or research team.
Megarbane Bruno, Professor
CONTACT
0149958442 ext. +33
Voicu Sebastian, MD
CONTACT
0149958442 ext. +33
Assistance Publique - Hôpitaux de Paris
Other
Reduction of Digestive Absorption of Toxic Substances by Combined Digestive Decontamination in Intensive Care - Randomized Single-center Study
Acronym: DIMREATOX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05471479
Anthrax, Bacillaceae Infections
Québec, Quebec, Canada
View Trial DetailsNCT04767776
Anthrax, Bacillaceae Infections
Saint-Etienne, France
View Trial DetailsNCT02657512
Anthrax, Bacillaceae Infections
Saint-Etienne, France
View Trial DetailsNCT00050310
Anthrax, Bacillaceae Infections
Bethesda, Maryland, United States
View Trial Details